CUTAQUIG ( DrugBank: - )

---

1 disease

ID	Disease name (Link within this page)	Number of trials
65	Primary immunodeficiency	2

65. Primary immunodeficiency

---

Clinical trials : 482 /  Drugs : 653 - (DrugBank : 119) / Drug target genes : 92 - Drug target pathways : 212

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03939533 (ClinicalTrials.gov)	October 17, 2019	3/5/2019	Study to Monitor Subcutaneous Human Immunoglobulin Administered at Modified Dosing Regimens in Patients With Primary Immunodeficiency Diseases	Clinical Phase 3 Study to Monitor the Safety, Tolerability, and Efficacy of Subcutaneous Human Immunoglobulin (CUTAQUIG®) Administered at Modified Dosing Regimens in Patients With Primary Immunodeficiency Diseases	Primary Immune Deficiency Disorder	Drug: CUTAQUIG	Octapharma	NULL	Completed	2 Years	75 Years	All	64	Phase 3	United States
2	NCT03677557 (ClinicalTrials.gov)	September 19, 2018	6/7/2018	Safety, Tolerability, Patient Satisfaction and Cost of 16.5% Subcutaneous Immunoglobulin (Cutaquig®) Treatment	Safety, Tolerability, Patient Satisfaction and Cost of 16.5% Subcutaneous Immunoglobulin (Cutaquig®) Treatment in Patients Who Did Not Tolerate Other 20% Subcutaneous Immunoglobulin Product(s)	Primary Immunodeficiency Disease;Secondary Immunodeficiency	Drug: 16,5% Cutaquig	Ottawa Hospital Research Institute	Octapharma	Recruiting	18 Years	N/A	All	30	Phase 4	Canada